<DOC>
	<DOCNO>NCT02248181</DOCNO>
	<brief_summary>Study document pramipexole dose monotherapy , occurrence fluctuation dyskinesias , dose increase deterioration Parkinson 's disease ( PD ) symptom , assessment reason add-on treatment L-Dopa dosing pramipexole L-Dopa give concomitantly .</brief_summary>
	<brief_title>Post Marketing Surveillance Study SifrolÂ® Patients With Idiopathic Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Diagnosis early stage idiopathic Parkinson 's Disease No pretreatment dopaminergic treatment ( de novo patient ) , Pretreatment LDopa dose &lt; 200 mg/d Treating physician ask consider regulation describe Summary Product Characteristics ( SmPC ) treatment pramipexole</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>